Compounds > sesamol
Page last updated: 2024-09-23

sesamol

Description

sesamol: constituent of sesame oil; RN given refers to parent cpd; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID68289
CHEMBL ID1517998
CHEBI ID9126
SCHEMBL ID20959
MeSH IDM0085102

Synonyms (94)

Synonym
phenol, 3,4-(methylenedioxy)-
SDCCGMLS-0066221.P001
brn 0127405
ai3-17298
3,4-methylenedioxyphenol
ccris 1386
nsc 59256
einecs 208-561-5
1,3-benzodioxol-5-ol
5-hydroxy-1,3-benzodioxole
nsc-59256
methylene ether of oxyhydroquinone
phenol,4-(methylenedioxy)-
wln: t56 bo do chj gq
3,4-(methylenedioxy)phenol
nsc59256
inchi=1/c7h6o3/c8-5-1-2-6-7(3-5)10-4-9-6/h1-3,8h,4h
NCGC00091628-01
533-31-3
sesamol
sesamol, 98%
sesamol, ion (1+)
sesamol titanium (+4)
sesamol sodium
sesamol lithium
AC-11668
bzx ,
S0418
A25062
5-hydroxy-1,3-benzodioxole;5-benzodioxolol;3,4-methylendioxyphenol;3,4-methylenedioxyphenol;3,4-(methylenedioxy)phenol, sesamol;1,3-benzodioxol-5-ol
AKOS005493905
NCGC00091628-02
2h-1,3-benzodioxol-5-ol
hsdb 8495
94iea0nv89 ,
unii-94iea0nv89
5-19-02-00532 (beilstein handbook reference)
CHEMBL1517998
chebi:9126 ,
dtxsid9021267 ,
NCGC00258763-01
cas-533-31-3
dtxcid101267
tox21_201211
STK568334
S3626
FT-0614403
benzodioxol-5-ol
3,4-methylenedioxyphenol [inci]
oristar mdp
4-hydroxy-1,2-methylenedioxybenzene
3,4-methylendioxyphenol
bdbm36291
BBL027539
SCHEMBL20959
3AO1
GF-0128
5-benzodioxolol
3,4-methylendioxy-phenol
5-hydroxy-benzo[1.3]dioxole
benzo[1,3]dioxol-5-ol
5-hydroxylbenzo[1,3]dioxolane
4,5-methylenedioxyphenol
3,4-methylenedioxy phenol
3,4 methylenedioxy phenol
5-hydroxy-1,3-benzodioxolane
benzo[d][1,3]dioxol-5-ol
3,4-methylenedioxy-phenol
(3,4-methylenedioxy)phenol
5-hydroxybenzo[1,3]dioxole
mfcd00005827
SY015819
W-105747
AC-35089
HY-N1417
F0001-1376
sesamol, purum, >=98.0% (gc)
SR-01000944738-1
sr-01000944738
sesamol, analytical standard
sesamol, vetec(tm) reagent grade, 98%
1,3-benzodioxol-5-ol (sesamol)
1,2,4-benzenetriol methylene ether
3,4-(methylenedioxy)-phenol
5-hydroxy-1, 3-benzodioxole
1,3-benzodioxol-5-ol, 9ci
1, 3-benzodioxol-5-ol
CS-0016841
Q418080
BCP14043
EN300-19382
1,3-dioxaindan-5-ol
CCG-266144
Z104473678

Research Excerpts

Overview

ExcerptReference
"Sesamol is a sesame seed constituent with reported activity against many types of cancer. "( Abd-Algaleel, SA; Abdel-Bar, HM; Hathout, RM; Kassem, DH; Metwally, AA, 2021)
"Sesamol is a lignan extracted from sesame oil and has been found to exert neuroprotective effects."( Gao, JM; Li, L; Liu, Q; Liu, X; Liu, Z; Mo, F; Xi, Y; Xie, T; Yuan, T, 2021)
"Sesamol is a phenolic antioxidant that can protect various organs from damage."( Ardekanian, M; Ghanbari, A; Hayat, P; Talebi, A; Zarbakhsh, S, 2022)
"Sesamol is a compound reported to have anti-melanogenesis and anti-melanoma actions. "( Bahrami, K; Järvinen, J; Rautio, J; Srisongkram, T; Timonen, J; Weerapreeyakul, N, 2022)
"Sesamol (SL), which is a natural phenolic compound, is known for its antioxidant properties, anti-inflammatory properties, and wound-healing abilities."( Ahmad, M; Kushwaha, P; Umam, N, 2023)
"Sesamol is a phenolic lignan isolated from "( Abu-Yousef, IA; Eltayeb, AE; Majdalawieh, AF; Yousef, SM, 2023)
"Sesamol is a phenolic compound isolated from natural food sesame (Sesamum indicum L.) with various biological activities."( Chen, J; Gao, X; He, J; Lin, T; Lin, X; Lyu, S; Wang, Q; Wang, X, 2023)
"Sesamol is a widely used antioxidant for the food and pharmaceutical industries. "( Chee, CF; Hazli, UHAM; Kong, KW; Leong, CO; Lo, KM; Mai, CW; Murthy, S; Rahman, NA, 2019)
"Sesamol is a safe, non-toxic chemical that mediates anti-inflammatory effects by down-regulating the transcription of inflammatory markers such as cytokines, redox status, protein kinases, and enzymes that promote inflammation."( Bosebabu, B; Chamallamudi, MR; Cheruku, SP; Kumar, N; Nampoothiri, M; Nandakumar, K; Parihar, VK; Shenoy, RR, 2020)
"Sesamol is a phenolic derivative. "( B R Santos, C; C Palheta, I; K L Vale, J; M Campos, J; M Herculano, A; Neto, AMJC; P P Silva, O; R Ferreira, L; R H M Oliveira, K; S Borges, R, 2020)
"Sesamol is a potential molecule for development of radioprotector due to its strong free radical scavenging and antioxidant properties."( Adhikari, JS; Chaudhury, NK; Choudhary, S; Kumar, A, 2018)
"Sesamol (SES) is an antioxidant and anti-inflammatory molecule as demonstrated in both in vitro and in vivo experimental models."( Balbinotti Andrade, CM; Chenet, AL; Duarte, AR; Roberto de Oliveira, M; Souza de Almeida, FJ, 2018)
"Sesamol is a natural phenolic compound and a major lignan isolated from sesame seeds (Sesamum indicum) and sesame oil. "( Majdalawieh, AF; Mansour, ZR, 2019)
"Sesamol is a phenolic component of sesame seed oil, which has been established as an antioxidant and also possesses potential for hepatoprotection. "( Kakkar, V; Kaur, IP; Khullar, N; Singh, N, 2016)
"Sesamol is a potent inhibitor of cytokine production as well as an antioxidant."( Chopra, K; Misra, S; Pal Kaur, I; Sachdeva, AK, 2015)
"Sesamol is a strong antioxidant phenolic compound found in sesame seed. "( Chen, F; Jiang, Y; Liu, B; Liu, J; Ma, X; Sun, P, 2015)
"Sesamol is a lignan isolated from sesame seed oil. "( Fang, LW; Huang, WC; Lai, XY; Li, ZY; Liou, CJ; Wu, XL, 2015)
"Sesamol is a natural phenolic compound extracted from "( Bonina, F; Crascì, L; Lauro, MR; Micicchè, L; Offerta, A; Panico, AM; Puglia, C; Puglisi, G, 2017)
"Sesamol is a phenolic lignan found in sesame seeds (Sesamum indicum L.) and sesame oil. "( Siriwarin, B; Weerapreeyakul, N, 2016)
"Sesamol lignan is a phenolic compound found in sesame seeds. "( Barusrux, S; Khamphio, M; Weerapreeyakul, N, 2016)
"Sesamol is a potent phenolic antioxidant which possesses antimutagenic, antihepatotoxic and antiaging properties. "( Chang, CC; Chiang, CW; Chou, DS; Fong, TH; Hsiao, G; Jayakumar, T; Lu, WJ; Ong, ET; Sheu, JR, 2010)
"Sesamol is a potent phenolic antioxidant contained only in processed sesame oil and possesses potent chemopreventive, antimutagenic, antihepatotoxic and antioxidation properties."( Pugalendi, KV; Vennila, L, 2012)
"Thus sesamol seems to be an almost equally potent chemopreventive agent."( Azuine, MA; Kapadia, GJ; Konoshima, T; Mukainaka, T; Nishino, H; Takasaki, M; Tokuda, H, 2002)
"Sesamol is a potent inhibitor of fungal fatty acid biosynthesis. "( Bilko, D; Jacklin, A; Newton, CJ; Ratledge, C; Welham, K, 2003)
"Sesamol is a component in the nutritional makeup of sesame that was identified as an antioxidant. "( Chang, H; Chen, PR; Lee, CC; Tsai, CE, 2005)
"Sesamol is a kind of antioxidant and exists in sesame oil. "( Kamogawa, A; Ohta, S; Sato, N; Shinoda, M; Suzuki, M, 1994)

Effects

ExcerptReference
"Sesamol has a potential as thrombolytic agent, nevertheless the current work highlights the significance of an appropriate dosage of sesamol when it is used as a therapeutic drug."( Girish, KS; Hemshekhar, M; Kemparaju, K; Kumar, MS; Naveen, S; Sunitha, K; Thushara, RM, 2013)
"Sesamol, however, has low intracellular drug concentration and fast excretion, which can limit its benefits in the clinic."( Bahrami, K; Järvinen, J; Rautio, J; Srisongkram, T; Timonen, J; Weerapreeyakul, N, 2022)
"CF-Sesamol has significant antioxidant and anti-inflammatory effects."( Cheng, L; Guo, M; He, Y; Jiang, H; Liu, J; Ren, C; Shi, Y; Sun, M; Wang, B; Wang, W; Wang, X; Xie, Y; Xu, X, 2021)
"Sesamol has also reduced formation of radiation induced γ-H2AX foci after 0.5 h in these organs and further lowered to respective control values at 24 h of WBI."( Adhikari, JS; Chaudhury, NK; Choudhary, S; Kumar, A, 2018)
"Sesamol has a potential as thrombolytic agent, nevertheless the current work highlights the significance of an appropriate dosage of sesamol when it is used as a therapeutic drug."( Girish, KS; Hemshekhar, M; Kemparaju, K; Kumar, MS; Naveen, S; Sunitha, K; Thushara, RM, 2013)
"Sesamol has cardioprotective activity through normalization of doxorubicin-induced-altered biochemical parameters."( Chennuru, A; Saleem, MT, 2013)
"Sesamol has been shown earlier to exhibit antimutagenic (reactive oxygen mediated) and antiageing activity in our lab and it has also been found to exert chemopreventive effect. "( Geetha, T; Pal, KI; Rohit, B, 2009)

Treatment

ExcerptReference
"Sesamol treatment improved spatial memory and learning ability in AD mice, improved neuronal damage, and decreased Aβ accumulation."( Gao, JM; Li, L; Liu, Q; Liu, X; Liu, Z; Mo, F; Xi, Y; Xie, T; Yuan, T, 2021)
"Sesamol-pretreated (10 μM) HeLa cells were exposed to 7.5 nM paclitaxel."( Sheng, J; Sun, Z; Wei, Y; Xiao, X; Xiong, J; Zhang, L, 2022)
"Sesamol treatment (0.05% w/v, in drinking water) suppressed d-galactose-induced liver damages and improved HO-1 and NQO1 mRNA levels."( Diao, Z; Liu, X; Liu, Z; Ren, B; Yuan, T; Zhang, C, 2018)
"Sesamol pre-treatment also alleviated the disturbed antioxidant milieu by preventing ROS production and improving endogenous enzyme levels."( Bansal, P; Kutty, NG; Nayak, PG; Pai, KS; Paul, P, 2013)
"the sesamol- and kojic-treated SK-MEL2 cells."( Barusrux, S; Srisayam, M; Tanthanuch, W; Thumanu, K; Weerapreeyakul, N, 2014)
"Sesamol treatment also showed recovery of relative spleen weight at 24h of WBI."( Adhikari, JS; Chaudhury, NK; Choudhary, S; Khan, S; Kumar, A; Selvan, TG; Tripathi, AM, 2015)
"Sesamol pre-treatment inhibited lipid peroxidation, translocation of gut bacteria to spleen, liver, and kidney, and enhanced regeneration of crypt cells in the GI system."( Adhikari, JS; Chaudhury, NK; Khan, S; Kumar, A; Rizvi, MA, 2015)
"Sesamol treatment reduced the negative impact of STZ-induced diabetes on tight junction protein expression in isolated cerebral microvessels."( Chua, MD; Huber, JD; Kelly, KA; Ptachcinski, RL; VanGilder, RL, 2009)
"Sesamol treatment may represent a novel approach to lowering the risk of or improving function in thromboembolism-related disorders."( Chang, CC; Chiang, CW; Chou, DS; Fong, TH; Hsiao, G; Jayakumar, T; Lu, WJ; Ong, ET; Sheu, JR, 2010)
"Sesamol pre-treatment restored oxidative defence possibly by its free radical scavenging activity as compared to the 3NP-treated group."( Kalonia, H; Kumar, A; Kumar, P, 2010)
"Sesamol treatment decreased IR, hyperinsulinemia, hyperglycemia, dyslipidemia, TNF-α, IL-6, leptin, resistin, highly sensitive C-reactive protein (hs-CRP), hepatic transaminases and alkaline phosphatase, along with normalization of adiponectin, nitric oxide and arterial pressures in a dose-dependent fashion."( Arya, DS; Bharti, S; Bhatia, J; Kumari, S; Malik, S; Nepal, S; Ray, R; Sharma, AK, 2012)
"Sesamol pretreated (1, 5 and 10 microg/ml) lymphocytes were exposed to different doses of gamma-radiation, i.e., 1, 2 and 4 Gray (Gy) and the cellular changes were estimated by using cytokinesis blocked micronucleus assay (MN), dicentric aberration (DC), thiobarbituric acid reactive substances (TBARS), reduced glutathione (GSH) and the activities of superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx). "( Menon, VP; Prasad, NR; Pugalendi, KV; Vasudev, V, 2005)
"Pretreatment with sesamol significantly reduced the serum creatinine and blood urea nitrogen levels, lipid peroxidation, restored levels of reduced glutathione and increased total renal nitric oxide levels."( Chopra, K; Gupta, A; Kaur, I; Sharma, S, 2009)
"Pretreatment with sesamol (0.85 mg/kg/day) significantly protected against all these effects."( Bianchini, A; Monserrat, JM, 2007)

Drug Classes (1)

ClassDescription
benzodioxoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (38)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency27.26380.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency8.99560.000221.22318,912.5098AID588515; AID588516; AID743036; AID743040; AID743042; AID743053
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency3.03890.000657.913322,387.1992AID1259377
progesterone receptorHomo sapiens (human)Potency60.63360.000417.946075.1148AID1346795
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency66.83970.001530.607315,848.9004AID1224848; AID1224849; AID1259403
estrogen nuclear receptor alphaHomo sapiens (human)Potency20.43050.000229.305416,493.5996AID743075; AID743078; AID743079
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency15.84890.001019.414170.9645AID588537
Histone H2A.xCricetulus griseus (Chinese hamster)Potency63.04380.039147.5451146.8240AID1224845; AID1224896
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency61.81960.000323.4451159.6830AID743065; AID743067
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency15.84890.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyphenol oxidase 2Agaricus bisporusIC50 (µMol)6.70000.03403.987110.0000AID1760270
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, POL polyproteinHuman immunodeficiency virus 1Kd5,500.00005,500.00005,500.00005,500.0000AID977611
Chain B, POL polyproteinHuman immunodeficiency virus 1Kd5,500.00005,500.00005,500.00005,500.0000AID977611
Chain A, POL polyproteinHuman immunodeficiency virus 1Kd5,500.00005,500.00005,500.00005,500.0000AID977611
Chain B, POL polyproteinHuman immunodeficiency virus 1Kd5,500.00005,500.00005,500.00005,500.0000AID977611
Chain A, POL polyproteinHuman immunodeficiency virus 1Kd5,500.00005,500.00005,500.00005,500.0000AID977611
Chain B, POL polyproteinHuman immunodeficiency virus 1Kd5,500.00005,500.00005,500.00005,500.0000AID977611
Chain A, POL polyproteinHuman immunodeficiency virus 1Kd5,500.00005,500.00005,500.00005,500.0000AID977611
Chain B, POL polyproteinHuman immunodeficiency virus 1Kd5,500.00005,500.00005,500.00005,500.0000AID977611
Chain A, POL polyproteinHuman immunodeficiency virus 1Kd5,500.00005,500.00005,500.00005,500.0000AID977611
Chain B, POL polyproteinHuman immunodeficiency virus 1Kd5,500.00005,500.00005,500.00005,500.0000AID977611
Integrase Human immunodeficiency virus 1Kd5,500.00000.00331.00983.0000AID1295720
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (57)

Assay IDTitleYearJournalArticle
AID1202866Antiatherogenic activity in high-fat diet fed Syrian hamster assessed as reduction of atherosclerotic lesions size in aortic arch at 100 mg/kg, po administered for 16 weeks by oil red o staining-based assay relative to high-fat diet fed control2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Sesamol reduces the atherogenicity of electronegative L5 LDL in vivo and in vitro.
AID1683550Antioxidant activity assessed as reduction in lipid peroxidation by measuring antiperoxide-index at 1.2 g/L by thiobarbituric acid method relative to control2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Preparations and antioxidant activities of sesamol and it's derivatives.
AID1683562Antioxidant activity assessed as superoxide anion radical scavenging rate at 1 g/L relative to control2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Preparations and antioxidant activities of sesamol and it's derivatives.
AID1683568Antioxidant activity assessed as hydroxyl radical scavenging rate at 1 g/L relative to control2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Preparations and antioxidant activities of sesamol and it's derivatives.
AID1683567Antioxidant activity assessed as superoxide anion radical scavenging rate at 0.2 g/L relative to control2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Preparations and antioxidant activities of sesamol and it's derivatives.
AID1683553Antioxidant activity assessed as reduction in lipid peroxidation by measuring antiperoxide-index at 0.6 g/L by thiobarbituric acid method relative to control2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Preparations and antioxidant activities of sesamol and it's derivatives.
AID1683569Antioxidant activity assessed as hydroxyl radical scavenging rate at 1.2 g/L relative to control2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Preparations and antioxidant activities of sesamol and it's derivatives.
AID1683555Antioxidant activity assessed as reduction in lipid peroxidation by measuring antiperoxide-index at 0.2 g/L by thiobarbituric acid method relative to control2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Preparations and antioxidant activities of sesamol and it's derivatives.
AID1202884Reversal of L5-induced Akt dephosphorylation in HAEC at 3 uM preincubated for 30 mins followed by L5 induction measured after 24 hrs by Western blot analysis2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Sesamol reduces the atherogenicity of electronegative L5 LDL in vivo and in vitro.
AID1202882Induction of eNOS phosphorylation in HAEC at 3 uM measured at 30 mins by Western blot analysis in presence of wortmannin and Akt inhibitor2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Sesamol reduces the atherogenicity of electronegative L5 LDL in vivo and in vitro.
AID1202862Antiatherogenic activity in high-fat diet fed Syrian hamster assessed as decrease in plasma very-low-density lipoprotein cholesterol level at 50 to 100 mg/kg, po administered for 16 weeks by automated analyzer relative to high-fat diet fed control2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Sesamol reduces the atherogenicity of electronegative L5 LDL in vivo and in vitro.
AID1295720Binding affinity to HIV integrase2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends.
AID1202867Antiatherogenic activity in high-fat diet fed Syrian hamster assessed as decrease in plasma L5 level at 50 mg/kg, po administered for 16 weeks by fast protein liquid chromatographic analysis (Rvb = 13.7%)2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Sesamol reduces the atherogenicity of electronegative L5 LDL in vivo and in vitro.
AID1683564Antioxidant activity assessed as superoxide anion radical scavenging rate at 0.8 g/L relative to control2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Preparations and antioxidant activities of sesamol and it's derivatives.
AID1683566Antioxidant activity assessed as superoxide anion radical scavenging rate at 0.6 g/L relative to control2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Preparations and antioxidant activities of sesamol and it's derivatives.
AID1683565Antioxidant activity assessed as superoxide anion radical scavenging rate at 0.4 g/L relative to control2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Preparations and antioxidant activities of sesamol and it's derivatives.
AID1202878Induction of eNOS phosphorylation in HAEC at 3 uM after 10 to 30 mins by Western blot analysis2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Sesamol reduces the atherogenicity of electronegative L5 LDL in vivo and in vitro.
AID1683571Antioxidant activity assessed as hydroxyl radical scavenging rate at 0.4 g/L relative to control2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Preparations and antioxidant activities of sesamol and it's derivatives.
AID779150Inhibition of Wnt/beta-catenin signaling pathway in human HEK293 cells at 20 uM after 24 hrs by dual luciferase reporter gene assay relative to vehicle-treated control2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Anti-proliferative activity of hydnocarpin, a natural lignan, is associated with the suppression of Wnt/β-catenin signaling pathway in colon cancer cells.
AID1683561Antioxidant activity assessed as reduction of potassium ferricyanide trivalent iron into potassium ferrocyanide bivalent iron and ferrous iron by measuring eliminate efficiency at 0.2 g/L relative to control2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Preparations and antioxidant activities of sesamol and it's derivatives.
AID1683557Antioxidant activity assessed as reduction of potassium ferricyanide trivalent iron into potassium ferrocyanide bivalent iron and ferrous iron by measuring eliminate efficiency at 1 g/L relative to control2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Preparations and antioxidant activities of sesamol and it's derivatives.
AID1202860Antiatherogenic activity in high-fat diet fed po dosed Syrian hamster assessed as decrease in plasma L5 level administered for 16 weeks by fast protein liquid chromatographic analysis2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Sesamol reduces the atherogenicity of electronegative L5 LDL in vivo and in vitro.
AID1202872Inhibition of LOX1-induced DiI-L5 endocytosis in HAEC at 3 uM preincubated for 30 mins followed by DiI-L5 treatment measured after 8 hrs by fluorescence microscopic analysis2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Sesamol reduces the atherogenicity of electronegative L5 LDL in vivo and in vitro.
AID1202881Induction of Akt phosphorylation in HAEC at 3 uM after 60 to 240 mins by Western blot analysis2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Sesamol reduces the atherogenicity of electronegative L5 LDL in vivo and in vitro.
AID1202876Activation of PI3K/Akt/eNOS signaling in HAEC assessed as inhibition of L5-induced caspase-3 activation preincubated for 30 mins followed by L5 induction measured after 24 hrs by Western blot analysis in presence of PI3K inhibitor wortmannin, Akt inhibito2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Sesamol reduces the atherogenicity of electronegative L5 LDL in vivo and in vitro.
AID1202873Inhibition of L5-induced LOX1 expression in HAEC at 0.3 to 3 uM by immunoblot analysis2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Sesamol reduces the atherogenicity of electronegative L5 LDL in vivo and in vitro.
AID1202857Toxicity in high-fat diet fed Syrian hamster assessed as mortality at 50 to 100 mg/kg, po administered for 16 weeks measured over 22 weeks2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Sesamol reduces the atherogenicity of electronegative L5 LDL in vivo and in vitro.
AID1202865Antiatherogenic activity in high-fat diet fed Syrian hamster assessed as reduction of atherosclerotic lesions size in aortic arch at 50 mg/kg, po administered for 16 weeks by oil red o staining-based assay relative to high-fat diet fed control2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Sesamol reduces the atherogenicity of electronegative L5 LDL in vivo and in vitro.
AID1202864Antiatherogenic activity in high-fat diet fed Syrian hamster assessed as decrease in plasma trigylceride level at 50 to 100 mg/kg, po administered for 16 weeks by automated analyzer relative to high-fat diet fed control2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Sesamol reduces the atherogenicity of electronegative L5 LDL in vivo and in vitro.
AID1683563Antioxidant activity assessed as superoxide anion radical scavenging rate at 1.2 g/L relative to control2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Preparations and antioxidant activities of sesamol and it's derivatives.
AID1683556Antioxidant activity assessed as reduction of potassium ferricyanide trivalent iron into potassium ferrocyanide bivalent iron and ferrous iron by measuring eliminate efficiency at 1.2 g/L relative to control2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Preparations and antioxidant activities of sesamol and it's derivatives.
AID1683560Antioxidant activity assessed as reduction of potassium ferricyanide trivalent iron into potassium ferrocyanide bivalent iron and ferrous iron by measuring eliminate efficiency at 0.4 g/L relative to control2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Preparations and antioxidant activities of sesamol and it's derivatives.
AID1683570Antioxidant activity assessed as hydroxyl radical scavenging rate at 0.8 g/L relative to control2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Preparations and antioxidant activities of sesamol and it's derivatives.
AID1202883Induction of Akt phosphorylation in HAEC at 3 uM measured at 30 mins by Western blot analysis in presence of wortmannin and Akt inhibitor2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Sesamol reduces the atherogenicity of electronegative L5 LDL in vivo and in vitro.
AID1202879Induction of eNOS phosphorylation in HAEC at 3 uM after 60 to 240 mins by Western blot analysis2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Sesamol reduces the atherogenicity of electronegative L5 LDL in vivo and in vitro.
AID1202871Inhibition of L5-induced caspase-3 activation in HAEC preincubated for 30 mins followed by L5 induction measured after 24 hrs by immunoblot analysis2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Sesamol reduces the atherogenicity of electronegative L5 LDL in vivo and in vitro.
AID1683559Antioxidant activity assessed as reduction of potassium ferricyanide trivalent iron into potassium ferrocyanide bivalent iron and ferrous iron by measuring eliminate efficiency at 0.6 g/L relative to control2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Preparations and antioxidant activities of sesamol and it's derivatives.
AID1683551Antioxidant activity assessed as reduction in lipid peroxidation by measuring antiperoxide-index at 1 g/L by thiobarbituric acid method relative to control2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Preparations and antioxidant activities of sesamol and it's derivatives.
AID1683572Antioxidant activity assessed as hydroxyl radical scavenging rate at 0.6 g/L relative to control2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Preparations and antioxidant activities of sesamol and it's derivatives.
AID1683558Antioxidant activity assessed as reduction of potassium ferricyanide trivalent iron into potassium ferrocyanide bivalent iron and ferrous iron by measuring eliminate efficiency at 0.8 g/L relative to control2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Preparations and antioxidant activities of sesamol and it's derivatives.
AID1202863Antiatherogenic activity in high-fat diet fed Syrian hamster assessed as decrease in plasma low-density lipoprotein cholesterol level at 50 to 100 mg/kg, po administered for 16 weeks by automated analyzer relative to high-fat diet fed control2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Sesamol reduces the atherogenicity of electronegative L5 LDL in vivo and in vitro.
AID1202874Inhibition of L5-activated LOX1-induced p38 MAPK phosphorylation in HAEC preincubated for 30 mins followed by L5 induction measured after 120 mins by Western blot analysis2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Sesamol reduces the atherogenicity of electronegative L5 LDL in vivo and in vitro.
AID1202858Toxicity in high-fat diet fed Syrian hamster assessed as change in body weight at 50 to 100 mg/kg, po administered for 16 weeks measured over 22 weeks2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Sesamol reduces the atherogenicity of electronegative L5 LDL in vivo and in vitro.
AID1683554Antioxidant activity assessed as reduction in lipid peroxidation by measuring antiperoxide-index at 0.4 g/L by thiobarbituric acid method relative to control2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Preparations and antioxidant activities of sesamol and it's derivatives.
AID1760270Inhibition of mushroom tyrosinase using L-tyrosine as substrate measured after 30 mins by microplate reader analysis2020European journal of medicinal chemistry, Sep-01, Volume: 201Kojic acid-natural product conjugates as mushroom tyrosinase inhibitors.
AID1202869Inhibition of L5-induced apoptosis in HAEC preincubated for 30 mins followed by L5 induction measured after 24 hrs by Hoechst 33342 and calcein-AM staining-based fluorescence microscopic analysis2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Sesamol reduces the atherogenicity of electronegative L5 LDL in vivo and in vitro.
AID1202861Antiatherogenic activity in high-fat diet fed Syrian hamster assessed as decrease in plasma total cholesterol level at 50 to 100 mg/kg, po administered for 16 weeks by automated analyzer relative to high-fat diet fed control2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Sesamol reduces the atherogenicity of electronegative L5 LDL in vivo and in vitro.
AID1202868Antiatherogenic activity in high-fat diet fed Syrian hamster assessed as decrease in plasma L5 level at 100 mg/kg, po administered for 16 weeks by fast protein liquid chromatographic analysis (Rvb = 13.7%)2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Sesamol reduces the atherogenicity of electronegative L5 LDL in vivo and in vitro.
AID1202880Induction of Akt phosphorylation in HAEC at 3 uM after 10 to 30 mins by Western blot analysis2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Sesamol reduces the atherogenicity of electronegative L5 LDL in vivo and in vitro.
AID1683573Antioxidant activity assessed as hydroxyl radical scavenging rate at 0.2 g/L relative to control2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Preparations and antioxidant activities of sesamol and it's derivatives.
AID1202875Activation of PI3K/Akt/eNOS signaling in HAEC assessed as inhibition of L5-induced p38 MAPK phosphorylation preincubated for 30 mins followed by L5 induction measured after 120 mins by Western blot analysis in presence of PI3K inhibitor wortmannin, Akt in2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Sesamol reduces the atherogenicity of electronegative L5 LDL in vivo and in vitro.
AID1683552Antioxidant activity assessed as reduction in lipid peroxidation by measuring antiperoxide-index at 0.8 g/L by thiobarbituric acid method relative to control2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Preparations and antioxidant activities of sesamol and it's derivatives.
AID1202870Antiatherogenic activity in high-fat diet fed Syrian hamster assessed as downregulation of active caspase-3 expression in aorta at 50 to 100 mg/kg, po administered for 16 weeks by immunohistochemical analysis2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Sesamol reduces the atherogenicity of electronegative L5 LDL in vivo and in vitro.
AID1202859Antiatherogenic activity in high-fat diet fed po dosed Syrian hamster assessed as decrease in total LDL electronegativity administered for 16 weeks by agarose gel electrophoresis2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Sesamol reduces the atherogenicity of electronegative L5 LDL in vivo and in vitro.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2011ChemMedChem, Feb-07, Volume: 6, Issue:2
Fragment-based design of ligands targeting a novel site on the integrase enzyme of human immunodeficiency virus 1.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (242)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (2.07)18.7374
1990's13 (5.37)18.2507
2000's43 (17.77)29.6817
2010's113 (46.69)24.3611
2020's68 (28.10)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.40%)5.53%
Reviews10 (4.05%)6.00%
Case Studies1 (0.40%)4.05%
Observational0 (0.00%)0.25%
Other235 (95.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
magnolol[no description available]medium10biphenyls
honokiol[no description available]medium10biphenyls
sesamin[no description available]medium160benzodioxoles;
furofuran;
lignan		antineoplastic agent;
neuroprotective agent;
plant metabolite
sesamolin[no description available]medium140benzodioxoles
schizandrin b[no description available]medium10aromatic ether;
cyclic acetal;
organic heterotetracyclic compound;
oxacycle;
tannin		anti-asthmatic agent;
anti-inflammatory agent;
antilipemic drug;
antioxidant;
apoptosis inhibitor;
hepatoprotective agent;
nephroprotective agent;
neuroprotective agent;
plant metabolite
schizandrin[no description available]medium10
paulownin[no description available]medium10
silybin[no description available]medium10
rosmarinic acid[no description available]medium10rosmarinic acidgeroprotector;
plant metabolite
aldosterone[no description available]medium10
pravastatin[no description available]medium10glycoside;
lignan
sb 203580[no description available]medium10imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide		EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent
lopinavir[no description available]medium10amphetamines;
dicarboxylic acid diamide		anticoronaviral agent;
antiviral drug;
HIV protease inhibitor
1-(2',6'-difluorophenyl)-1h,3h-thiazolo(3,4-a)benzimidazole[no description available]medium10
darunavir[no description available]medium10carbamate ester;
furofuran;
sulfonamide		antiviral drug;
HIV protease inhibitor
ritonavir[no description available]medium101,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas		antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic
5-(1,1-dioxido-1,2-thiazinan-2-yl)-n-(4-fluorobenzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamide[no description available]medium10
bms-488043[no description available]medium10
bms 806[no description available]medium10
bms-626529[no description available]medium10
vanillin[no description available]medium30benzaldehydes;
monomethoxybenzene;
phenols		anti-inflammatory agent;
anticonvulsant;
antioxidant;
flavouring agent;
plant metabolite
kojic acid[no description available]medium204-pyranones;
enol;
primary alcohol		Aspergillus metabolite;
EC 1.10.3.1 (catechol oxidase) inhibitor;
EC 1.10.3.2 (laccase) inhibitor;
EC 1.13.11.24 (quercetin 2,3-dioxygenase) inhibitor;
EC 1.14.18.1 (tyrosinase) inhibitor;
EC 1.4.3.3 (D-amino-acid oxidase) inhibitor;
NF-kappaB inhibitor;
skin lightening agent
isovanillin[no description available]medium10benzaldehydes;
monomethoxybenzene;
phenols		animal metabolite;
antidiarrhoeal drug;
antifungal agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
HIV protease inhibitor;
plant metabolite
isoeugenol[no description available]medium20isoeugenolplant metabolite
7-hydroxycoumarin[no description available]medium10hydroxycoumarinfluorescent probe;
food component;
plant metabolite
allopurinol[no description available]medium40nucleobase analogue;
organic heterobicyclic compound		antimetabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
gout suppressant;
radical scavenger
uric acid[no description available]medium10uric acidEscherichia coli metabolite;
human metabolite;
mouse metabolite
lignans[no description available]medium210
malondialdehyde[no description available]medium70dialdehydebiomarker
paclitaxel[no description available]medium10taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
thioacetamide[no description available]medium10thiocarboxamidehepatotoxic agent
glycerol[no description available]medium10alditol;
triol		algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent
leucine[no description available]medium10amino acid zwitterion;
L-alpha-amino acid;
leucine;
proteinogenic amino acid;
pyruvate family amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
phenylalanine[no description available]medium10amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid		algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
carbamates[no description available]medium10amino-acid anion
scopolamine hydrobromide[no description available]medium10
manganese[no description available]medium10elemental manganese;
manganese group element atom		Escherichia coli metabolite;
micronutrient
transforming growth factor beta[no description available]medium10
sorbitan monooleate[no description available]medium10fatty acid ester
chitosan[no description available]medium30
retinol[no description available]medium10retinol;
vitamin A		human metabolite;
mouse metabolite;
plant metabolite
beta carotene[no description available]medium10carotenoid beta-end derivative;
cyclic carotene		antioxidant;
biological pigment;
cofactor;
ferroptosis inhibitor;
human metabolite;
mouse metabolite;
plant metabolite;
provitamin A
tocopherols[no description available]medium50
d-alpha tocopherol[no description available]medium110alpha-tocopherolalgal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite
perillyl alcohol[no description available]medium10limonene monoterpenoidplant metabolite;
volatile oil component
peroxynitrous acid[no description available]medium20nitrogen oxoacid
hexacyanoferrate iii[no description available]medium10
acetylcellulose[no description available]medium10
cellulose[no description available]medium10glycoside
trans-4-coumaric acid[no description available]medium104-coumaric acidfood component;
mouse metabolite;
plant metabolite
ferulic acid[no description available]medium20ferulic acidsanti-inflammatory agent;
antioxidant;
apoptosis inhibitor;
cardioprotective agent;
MALDI matrix material;
plant metabolite
protocatechuic acid[no description available]medium10catechols;
dihydroxybenzoic acid		antineoplastic agent;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor;
human xenobiotic metabolite;
plant metabolite
gallic acid[no description available]medium40trihydroxybenzoic acidantineoplastic agent;
antioxidant;
apoptosis inducer;
astringent;
cyclooxygenase 2 inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
geroprotector;
human xenobiotic metabolite;
plant metabolite
phenol[no description available]medium10phenolsantiseptic drug;
disinfectant;
human xenobiotic metabolite;
mouse metabolite
quercetin[no description available]medium107-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
4-hydroxybenzoic acid[no description available]medium10monohydroxybenzoic acidalgal metabolite;
plant metabolite
pinoresinol diglucoside[no description available]medium10
propylparaben[no description available]medium10benzoate ester;
paraben;
phenols		antifungal agent;
antimicrobial agent
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid[no description available]medium10chromanol;
monocarboxylic acid;
phenols		antioxidant;
ferroptosis inhibitor;
neuroprotective agent;
radical scavenger;
Wnt signalling inhibitor
hydroxyl radical[no description available]medium80oxygen hydride;
oxygen radical;
reactive oxygen species
coniferyl alcohol[no description available]medium10guaiacols;
phenylpropanoid		animal metabolite;
monolignol;
mouse metabolite;
pheromone;
plant metabolite;
volatile oil component
sesaminol[no description available]medium20benzodioxoles;
furofuran;
organic hydroxy compound		antioxidant;
plant metabolite
tyloxapol[no description available]medium10
clofibric acid[no description available]medium10aromatic ether;
monocarboxylic acid;
monochlorobenzenes		anticholesteremic drug;
antilipemic drug;
antineoplastic agent;
herbicide;
marine xenobiotic metabolite;
PPARalpha agonist
aluminum[no description available]medium10boron group element atom;
elemental aluminium;
metal atom
stearic acid[no description available]medium10long-chain fatty acid;
saturated fatty acid;
straight-chain saturated fatty acid		algal metabolite;
Daphnia magna metabolite;
human metabolite;
plant metabolite
sirolimus[no description available]medium10antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol		antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
titanium[no description available]medium20titanium group element atom
titanium dioxide[no description available]medium20titanium oxidesfood colouring
dimedone[no description available]medium10
methane[no description available]medium20alkane;
gas molecular entity;
mononuclear parent hydride;
one-carbon compound		bacterial metabolite;
fossil fuel;
greenhouse gas
tiletamine hydrochloride[no description available]medium20
xanthenes[no description available]medium30xanthene
hydrogen[no description available]medium10elemental hydrogen;
elemental molecule;
gas molecular entity		antioxidant;
electron donor;
food packaging gas;
fuel;
human metabolite
tricalcium phosphate[no description available]medium10calcium phosphate
caseins[no description available]medium10
zinc protoporphyrin ix[no description available]medium10
4-hydroxycoumarin[no description available]medium10hydroxycoumarin
salicylaldehyde[no description available]medium20hydroxybenzaldehydenematicide;
plant metabolite
galactose[no description available]medium10D-galactose;
galactopyranose		Escherichia coli metabolite;
mouse metabolite
sethoxydim[no description available]medium10organic hydroxy compound
malonyl coenzyme a[no description available]medium10malonyl-CoAsEC 2.3.1.21 (carnitine O-palmitoyltransferase) inhibitor;
Escherichia coli metabolite;
metabolite;
mouse metabolite
lactoferrin[no description available]medium10
selenium[no description available]medium10chalcogen;
nonmetal atom		micronutrient
cadmium sulfide[no description available]medium10cadmium molecular entity
buspirone[no description available]medium10azaspiro compound;
N-alkylpiperazine;
N-arylpiperazine;
organic heteropolycyclic compound;
piperidones;
pyrimidines		anxiolytic drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
sedative;
serotonergic agonist
nitrites[no description available]medium50monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species		human metabolite
desoxycorticosterone acetate[no description available]medium10corticosteroid hormone
ascorbic acid[no description available]medium80ascorbic acid;
vitamin C		coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent
piperidines[no description available]medium10
sr 144528[no description available]medium10bridged compound;
monochlorobenzenes;
pyrazoles;
secondary carboxamide		CB2 receptor antagonist;
EC 2.3.1.26 (sterol O-acyltransferase) inhibitor
am 251[no description available]medium10amidopiperidine;
carbohydrazide;
dichlorobenzene;
organoiodine compound;
pyrazoles		antidepressant;
antineoplastic agent;
apoptosis inducer;
CB1 receptor antagonist
amitriptyline[no description available]medium10carbotricyclic compound;
tertiary amine		adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
tropomyosin-related kinase B receptor agonist;
xenobiotic
flurazepam[no description available]medium101,4-benzodiazepinone;
monofluorobenzenes;
organochlorine compound;
tertiary amino compound		anticonvulsant;
anxiolytic drug;
GABAA receptor agonist;
sedative
cytochrome c-t[no description available]medium10
dinitrochlorobenzene[no description available]medium10C-nitro compound;
monochlorobenzenes		allergen;
epitope;
sensitiser
naringenin[no description available]medium10(2S)-flavan-4-one;
naringenin		expectorant;
plant metabolite
rotenone[no description available]medium10organic heteropentacyclic compound;
rotenones		antineoplastic agent;
metabolite;
mitochondrial NADH:ubiquinone reductase inhibitor;
phytogenic insecticide;
piscicide;
toxin
thiourea[no description available]medium20one-carbon compound;
thioureas;
ureas		antioxidant;
chromophore
isatin[no description available]medium10indoledioneEC 1.4.3.4 (monoamine oxidase) inhibitor;
plant metabolite
mocetinostat[no description available]medium20aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
acetic acid[no description available]medium10monocarboxylic acidantimicrobial food preservative;
Daphnia magna metabolite;
food acidity regulator;
protic solvent
crocin[no description available]medium11
1,1-diphenyl-2-picrylhydrazyl[no description available]medium60
2-tert-butylhydroquinone[no description available]medium40hydroquinonesfood antioxidant
carnosine[no description available]medium10amino acid zwitterion;
dipeptide		anticonvulsant;
antineoplastic agent;
antioxidant;
Daphnia magna metabolite;
geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent
scandium[no description available]medium10d-block element atom;
rare earth metal atom;
scandium group element atom
carbon tetrachloride[no description available]medium30chlorocarbon;
chloromethanes		hepatotoxic agent;
refrigerant
gamma-tocopherol[no description available]medium10tocopherol;
vitamin E		algal metabolite;
food antioxidant;
plant metabolite
melatonin[no description available]medium20acetamides;
tryptamines		anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger
dinoprostone[no description available]medium30prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
D-fructopyranose[no description available]medium10cyclic hemiketal;
D-fructose;
fructopyranose		sweetening agent
nitrilotriacetic acid[no description available]medium20NTA;
tricarboxylic acid		carcinogenic agent;
nephrotoxic agent
ferric nitrilotriacetate[no description available]medium20iron chelatecarcinogenic agent;
mutagen
2,2'-azobis(2-amidinopropane)[no description available]medium10monoazo compound
acetaminophen[no description available]medium20acetamides;
phenols		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
phytoestrogens[no description available]medium10
lysine[no description available]medium10aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid		algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
methionine[no description available]medium10aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid		antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical
3-nitropropionic acid[no description available]medium20C-nitro compoundantimycobacterial drug;
EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor;
mycotoxin;
neurotoxin
ethidium[no description available]medium10phenanthridinesfluorochrome;
intercalator
dihydroethidium[no description available]medium10
carbon monoxide[no description available]medium20carbon oxide;
gas molecular entity;
one-carbon compound		biomarker;
EC 1.9.3.1 (cytochrome c oxidase) inhibitor;
human metabolite;
ligand;
metabolite;
mitochondrial respiratory-chain inhibitor;
mouse metabolite;
neurotoxin;
neurotransmitter;
P450 inhibitor;
probe;
signalling molecule;
vasodilator agent
sulfamic acid[no description available]medium10sulfamic acids
2-naphthol[no description available]medium10naphtholantinematodal drug;
genotoxin;
human urinary metabolite;
human xenobiotic metabolite;
mouse metabolite;
radical scavenger
cyclic gmp[no description available]medium203',5'-cyclic purine nucleotide;
guanyl ribonucleotide		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
anisole[no description available]medium10monomethoxybenzeneplant metabolite
tert-butoxy[no description available]medium10
bisphenol a-glycidyl methacrylate[no description available]medium10diarylmethane
isoproterenol[no description available]medium40catechols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent
4-anisidine[no description available]medium10methoxybenzenes;
primary amino compound;
substituted aniline		genotoxin;
reagent
hydroxyproline[no description available]medium104-hydroxyproline;
L-alpha-amino acid zwitterion		human metabolite;
mouse metabolite;
plant metabolite
cardiovascular agents[no description available]medium10
acetylcysteine[no description available]medium10acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
ng-nitroarginine methyl ester[no description available]medium10alpha-amino acid ester;
L-arginine derivative;
methyl ester;
N-nitro compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor
arginine[no description available]medium10arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
monocrotaline[no description available]medium10pyrrolizidine alkaloid
2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid[no description available]medium10
thiazoles[no description available]medium101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
phosphatidylcholines[no description available]medium101,2-diacyl-sn-glycero-3-phosphocholine
ceruletide[no description available]medium10oligopeptidediagnostic agent;
gastrointestinal drug
hexylresorcinol[no description available]medium10resorcinols
2-methylpentane[no description available]medium10alkane
geraniol[no description available]medium103,7-dimethylocta-2,6-dien-1-ol;
monoterpenoid;
primary alcohol		allergen;
fragrance;
plant metabolite;
volatile oil component
carvacrol[no description available]medium10botanical anti-fungal agent;
p-menthane monoterpenoid;
phenols		agrochemical;
antimicrobial agent;
flavouring agent;
TRPA1 channel agonist;
volatile oil component
limonene[no description available]medium10cycloalkene;
p-menthadiene		human metabolite
thymol[no description available]medium10monoterpenoid;
phenols		volatile oil component
benzophenone[no description available]medium10benzophenonesphotosensitizing agent;
plant metabolite
methylene blue[no description available]medium20organic chloride saltacid-base indicator;
antidepressant;
antimalarial;
antimicrobial agent;
antioxidant;
cardioprotective agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 4.6.1.2 (guanylate cyclase) inhibitor;
fluorochrome;
histological dye;
neuroprotective agent;
physical tracer
9,10-dimethyl-1,2-benzanthracene[no description available]medium10ortho-fused polycyclic arene;
tetraphenes		carcinogenic agent
tetradecanoylphorbol acetate[no description available]medium10acetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester		antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator
resveratrol[no description available]medium10resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger
stilbenes[no description available]medium10stilbene
piperonyl butoxide[no description available]medium20benzodioxolespesticide synergist
pyrethrins[no description available]medium10
gamma-cyclodextrin[no description available]medium10cyclodextrin
singlet oxygen[no description available]medium10chalcogen;
monoatomic oxygen;
nonmetal atom		macronutrient
rubrene[no description available]medium10
chlorophyll a[no description available]medium10chlorophyll;
methyl ester		cofactor
caryophyllene[no description available]medium10
humulene[no description available]medium10alpha-humulene
zerumbone[no description available]medium10cyclic ketone;
sesquiterpenoid		anti-inflammatory agent;
glioma-associated oncogene inhibitor;
plant metabolite
sesquiterpenes[no description available]medium10
deoxyribose[no description available]medium10deoxypentosehuman metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
capsaicin[no description available]medium10capsaicinoidnon-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker
wortmannin[no description available]medium10acetate ester;
cyclic ketone;
delta-lactone;
organic heteropentacyclic compound		anticoronaviral agent;
antineoplastic agent;
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector;
Penicillium metabolite;
radiosensitizing agent
methyl parathion[no description available]medium10C-nitro compound;
organic thiophosphate;
organothiophosphate insecticide		acaricide;
agrochemical;
antifungal agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
environmental contaminant;
genotoxin
1-anilino-8-naphthalenesulfonate[no description available]medium10aminonaphthalene;
naphthalenesulfonic acid		fluorescent probe
phytosterols[no description available]medium10
octanoic acid[no description available]medium10medium-chain fatty acid;
straight-chain saturated fatty acid		antibacterial agent;
Escherichia coli metabolite;
human metabolite
caprylates[no description available]medium10fatty acid anion 8:0;
straight-chain saturated fatty acid anion		human metabolite;
Saccharomyces cerevisiae metabolite
ethylphenylpropiolate[no description available]medium10
warfarin[no description available]medium20benzenes;
hydroxycoumarin;
methyl ketone
diclofenac[no description available]medium10amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
coumarin[no description available]medium10coumarinsfluorescent dye;
human metabolite;
plant metabolite
phytic acid[no description available]medium10inositol phosphate
diethyl maleate[no description available]medium10ethyl ester;
maleate ester		glutathione depleting agent
methylnitronitrosoguanidine[no description available]medium10nitroso compoundalkylating agent
catechol[no description available]medium50catecholsallelochemical;
genotoxin;
plant metabolite
caffeic acid[no description available]medium40caffeic acidgeroprotector;
mouse metabolite
hydroquinone[no description available]medium10benzenediol;
hydroquinones		antioxidant;
carcinogenic agent;
cofactor;
Escherichia coli metabolite;
human xenobiotic metabolite;
mouse metabolite;
skin lightening agent
nadp[no description available]medium20
1,3-benzodioxole[no description available]medium20benzodioxole
mequinol[no description available]medium10methoxybenzenes;
phenols		metabolite
linoleic acid[no description available]medium10octadecadienoic acid;
omega-6 fatty acid		algal metabolite;
Daphnia galeata metabolite;
plant metabolite
arachidonic acid[no description available]medium10icosa-5,8,11,14-tetraenoic acid;
long-chain fatty acid;
omega-6 fatty acid		Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite;
mouse metabolite
tert-butylhydroperoxide[no description available]medium10alkyl hydroperoxideantibacterial agent;
oxidising agent
carbenoxolone sodium[no description available]medium10triterpenoid
3,4-methylenedioxyamphetamine[no description available]medium10benzodioxoles
bromodeoxyuridine[no description available]medium10pyrimidine 2'-deoxyribonucleosideantimetabolite;
antineoplastic agent
diethylnitrosamine[no description available]medium10nitrosaminecarcinogenic agent;
hepatotoxic agent;
mutagen
thymidine[no description available]medium10pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
adenosine[no description available]medium10adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
isosafrole[no description available]medium10benzodioxoles
safrole[no description available]medium10benzodioxolesflavouring agent;
insecticide;
metabolite;
plant metabolite
piperonal[no description available]medium10arenecarbaldehyde;
benzodioxoles		fragrance;
insect repellent;
plant metabolite
n-methyl-3,4-methylenedioxyamphetamine[no description available]low00amphetamines;
benzodioxoles		neurotoxin
bendiocarb[no description available]low00benzodioxoles;
carbamate ester		agrochemical;
carbamate insecticide;
EC 3.1.1.7 (acetylcholinesterase) inhibitor
fipexide[no description available]low00benzodioxoles
5-(1,3-benzodioxol-5-yl)-1-(1-piperidinyl)-1-penta-2,4-dienone[no description available]low00benzodioxoles
protokylol[no description available]low00benzodioxoles
piperonylic acid[no description available]low00aromatic carboxylic acid;
benzodioxoles;
monocarboxylic acid		antifungal agent;
EC 1.14.14.91 ( trans-cinnamate 4-monooxygenase) inhibitor;
plant metabolite;
vulnerary
dihydrosafrole[no description available]low00benzodioxoles
sulfoxide[no description available]low00benzodioxoles
Dillapiole[no description available]low00benzodioxolesmetabolite
piperonyl alcohol[no description available]low00benzodioxoles
apiole[no description available]low00benzodioxolesmetabolite
paroxetine[no description available]low00aromatic ether;
benzodioxoles;
organofluorine compound;
piperidines		antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor
oxmetidine[no description available]low00benzodioxoles;
imidazoles;
pyrimidone		anti-ulcer drug;
H2-receptor antagonist
3,4-Methylenedioxyacetophenone[no description available]low00benzodioxoles
fludioxonil[no description available]low00benzodioxoles;
nitrile;
organofluorine compound;
pyrroles		androgen antagonist;
antifungal agrochemical;
estrogen receptor agonist
bursehernin[no description available]low00aromatic ether;
benzodioxoles;
butan-4-olide;
lignan		plant metabolite
sarisan[no description available]low00benzodioxoles
3,4-methylenedioxyethamphetamine[no description available]low00benzodioxoles;
secondary amino compound
tadalafil[no description available]low00benzodioxoles;
pyrazinopyridoindole		EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
cubebin[no description available]low00benzodioxoles;
cyclic acetal;
lactol;
lignan;
secondary alcohol		analgesic;
anti-inflammatory agent;
antimicrobial agent;
histamine antagonist;
plant metabolite;
trypanocidal drug
5,6-methylenedioxy-2-aminoindane[no description available]low00benzodioxoles
1-(3,4-methylenedioxyphenyl)-2-butanamine[no description available]low00benzodioxoles
1-(1,3-benzodioxol-5-yl)-3-(1-piperidinyl)-1-propanone[no description available]low00benzodioxoles
ly 300164[no description available]low00benzodioxoles
pluviatolide[no description available]low00aromatic ether;
benzodioxoles;
butan-4-olide;
lignan;
phenols		plant metabolite
helioxanthin[no description available]low00benzodioxoles;
furonaphthodioxole;
lignan		anti-HBV agent;
antineoplastic agent;
plant metabolite
enrasentan[no description available]low00aromatic ether;
benzodioxoles;
indanes;
monocarboxylic acid;
monomethoxybenzene;
primary alcohol		antihypertensive agent;
endothelin receptor antagonist
kobusin[no description available]low00benzodioxoles;
dimethoxybenzene;
furofuran;
lignan		plant metabolite
dihydrocubebin[no description available]low00benzodioxoles;
butanediols;
glycol;
lignan
tbc-11251[no description available]low00benzodioxoles
5-(1,3-benzodioxol-5-yl)-N-(2,4-dimethylphenyl)-1,3,4-oxadiazol-2-amine[no description available]low00benzodioxoles
taiwanin c[no description available]low00benzodioxoles;
furonaphthodioxole;
lignan		antineoplastic agent;
plant metabolite;
platelet aggregation inhibitor
yatein[no description available]low00benzodioxoles;
butan-4-olide;
lignan;
methoxybenzenes		plant metabolite
hinokinin[no description available]low00benzodioxoles;
gamma-lactone;
lignan		trypanocidal drug
egonol[no description available]low001-benzofurans;
aromatic ether;
benzodioxoles;
primary alcohol		plant metabolite
Tetrahydropiperine[no description available]low00benzodioxoles
kakoul[no description available]low00benzodioxoles
6-nitro-1,3-benzodioxol-5-amine[no description available]low00benzodioxoles
safrazine hydrochloride[no description available]low00benzodioxoles
piperyline[no description available]low00benzodioxoles;
N-acylpyrrolidine;
pyrrolidine alkaloid;
tertiary carboxamide		antifungal agent;
apoptosis inducer;
plant metabolite
piperine[no description available]low00benzodioxoles;
N-acylpiperidine;
piperidine alkaloid;
tertiary carboxamide		food component;
human blood serum metabolite;
NF-kappaB inhibitor;
plant metabolite
ilepcimide[no description available]low00benzodioxoles
4-(4-fluorophenyl)-6-methyl-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylic acid 1,3-benzodioxol-5-ylmethyl ester[no description available]low00benzodioxoles
N-(1,3-benzodioxol-5-yl)-2-[2-(3-chloro-4-methylanilino)-2-oxoethyl]sulfinylacetamide[no description available]low00benzodioxoles
5-(1,3-benzodioxol-5-yl)-1-methyl-2-imidazolamine[no description available]low00benzodioxoles
N-(1,3-benzodioxol-5-yl)-1-[(4-fluorophenyl)methyl]-4-triazolecarboxamide[no description available]low00benzodioxoles
N-(1,3-benzodioxol-5-yl)-5-bromo-3-pyridinecarboxamide[no description available]low00benzodioxoles
4-(1,3-benzodioxol-5-yl)-6-methyl-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylic acid ethyl ester[no description available]low00benzodioxoles
3-(1,3-benzodioxol-5-ylmethyl)-4,10-dihydro-2H-[1,3,5]triazino[1,2-a]benzimidazole[no description available]low00benzodioxoles
6-[[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]methyl]-N2-(3-methylphenyl)-1,3,5-triazine-2,4-diamine[no description available]low00benzodioxoles
5-(1,3-benzodioxol-5-yl)-2-[(2-chloro-6-fluorophenyl)methyl]tetrazole[no description available]low00benzodioxoles
1-(1,3-benzodioxol-5-yl)-4-hydroxy-3-pyrazolecarboxylic acid ethyl ester[no description available]low00benzodioxoles
N-(5-methyl-3-isoxazolyl)-1,3-benzodioxole-5-carboxamide[no description available]low00benzodioxoles
1-(3-pyridinylmethyl)-3-[2-(trifluoromethyl)-1,3-benzodioxol-2-yl]urea[no description available]low00benzodioxoles
N-(1,3-benzodioxol-5-ylmethyl)-1H-benzimidazol-2-amine[no description available]low00benzodioxoles
1-[(1,3-benzodioxol-5-ylmethylamino)-sulfanylidenemethyl]-4-piperidinecarboxamide[no description available]low00benzodioxoles
N-(1,3-benzodioxol-5-yl)-2-(2,4-dimethylphenoxy)acetamide[no description available]low00benzodioxoles
N-(1,3-benzodioxol-5-yl)-5-methyl-2-furancarboxamide[no description available]low00benzodioxoles
N-(1,3-benzodioxol-5-yl)-4-(4-morpholinylmethyl)benzamide[no description available]low00benzodioxoles
N-[[(phenylmethyl)amino]-sulfanylidenemethyl]-1,3-benzodioxole-5-carboxamide[no description available]low00benzodioxoles
N-(1,3-benzodioxol-5-yl)-4-(2-furanylmethyl)-1-piperazinecarbothioamide[no description available]low00benzodioxoles
1-(1,3-benzodioxol-5-yl)-3-(3-pyridinylmethyl)urea[no description available]low00benzodioxoles
1-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-2-[(4-chlorophenyl)methylthio]ethanone[no description available]low00benzodioxoles
2-(1,3-benzodioxol-5-yl)-N-[(2-ethoxyphenyl)methyl]-N-(2-pyridinylmethyl)ethanamine[no description available]low00benzodioxoles
N-(6-acetyl-1,3-benzodioxol-5-yl)-2-[(5-methyl-1,3,4-thiadiazol-2-yl)thio]acetamide[no description available]low00benzodioxoles
3-[[4-(1,3-benzodioxol-5-yl)-6-(trifluoromethyl)-2-pyrimidinyl]thio]-N-(2-furanylmethyl)propanamide[no description available]low00benzodioxoles
[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-[5-[(4-chlorophenoxy)methyl]-2-furanyl]methanone[no description available]low00benzodioxoles
N-(3-isoxazolyl)-1,3-benzodioxole-5-carboxamide[no description available]low00benzodioxoles
N-[2-[(phenylmethyl)amino]-1,3-benzodioxol-2-yl]carbamic acid ethyl ester[no description available]low00benzodioxoles
N-[2-(propan-2-ylamino)-1,3-benzodioxol-2-yl]carbamic acid ethyl ester[no description available]low00benzodioxoles
N-(1,3-benzodioxol-5-ylmethyl)-2-chloro-3-pyridinecarboxamide[no description available]low00benzodioxoles
N-[5-(2-methoxyethylthio)-1,3,4-thiadiazol-2-yl]-1,3-benzodioxole-5-carboxamide[no description available]low00benzodioxoles
2-pyrazinecarboxylic acid [2-(1,3-benzodioxol-5-ylamino)-2-oxoethyl] ester[no description available]low00benzodioxoles
2-[[5-(1,3-benzodioxol-5-yl)-1,3,4-oxadiazol-2-yl]thio]-N-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]acetamide[no description available]low00benzodioxoles
N-(1,3-benzodioxol-5-yl)-2-chloro-N-[(2-prop-2-enoxyphenyl)methyl]acetamide[no description available]low00benzodioxoles
N-(3-pyridinylmethyl)-1,3-benzodioxol-5-amine[no description available]low00benzodioxoles
2-(1,3-benzodioxol-5-yl)-5-[[5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl]methylthio]-1,3,4-oxadiazole[no description available]low00benzodioxoles
3,4-dimethyl-6-(6-nitro-1,3-benzodioxol-5-yl)-2-oxo-1,6-dihydropyrimidine-5-carboxylic acid propyl ester[no description available]low00benzodioxoles
6-amino-4-(1,3-benzodioxol-5-yl)-5-cyano-2-methyl-4H-pyran-3-carboxylic acid 2-methoxyethyl ester[no description available]low002-methoxyethyl ester;
benzodioxoles
4-(1,3-benzodioxol-5-yl)-6-[[2-(4-chlorophenyl)ethylamino]methyl]-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylic acid ethyl ester[no description available]low00benzodioxoles
acetic acid [2-(1,3-benzodioxol-5-ylmethylamino)-2-oxoethyl] ester[no description available]low00benzodioxoles
N-(2,2-difluoro-1,3-benzodioxol-5-yl)-2-[2-[2-(4-morpholinyl)-2-oxoethyl]-1-benzimidazolyl]acetamide[no description available]low00benzodioxoles
N-(1,3-benzodioxol-5-ylmethyl)-4-benzofuro[3,2-d]pyrimidinamine[no description available]low00benzodioxoles
2-(1,3-benzodioxol-5-yl)-5-[[2-(4-methoxyphenyl)-4,5-dihydrothiazol-5-yl]methylthio]-1,3,4-oxadiazole[no description available]low00benzodioxoles
N-(1,3-benzodioxol-5-ylmethyl)-N-[2-(cyclohexylamino)-2-oxo-1-pyridin-4-ylethyl]-2,2,2-trifluoroacetamide[no description available]low00benzodioxoles;
pyridines;
secondary carboxamide;
tertiary carboxamide;
trifluoroacetamide
N-(1,3-benzodioxol-5-yl)-2-(5-methyl-2-furanyl)-3-imidazo[1,2-a]pyrimidinamine[no description available]low00benzodioxoles
N-(1,3-benzodioxol-5-yl)-3-(1-ethyl-5-methyl-4-pyrazolyl)-4,5-dihydroisoxazole-5-carboxamide[no description available]low00benzodioxoles
4-[2-[[2-[[4-(1,3-benzodioxol-5-yl)-2-thiazolyl]amino]-2-oxoethyl]thio]-1-oxoethyl]-1-piperazinecarboxylic acid ethyl ester[no description available]low00benzodioxoles
6-(1,3-benzodioxol-5-ylmethylamino)-3-(2-methylphenyl)-1H-pyrimidine-2,4-dione[no description available]low00benzodioxoles
N-(1,3-benzodioxol-5-yl)-5-oxo-2,3-dihydrothiazolo[3,2-a]pyrimidine-6-carboxamide[no description available]low00benzodioxoles
N-(1,3-benzodioxol-5-ylmethyl)-4-nitroaniline[no description available]low00benzodioxoles
6-[(4-bromophenyl)-(1-pyrrolidinyl)methyl]-1,3-benzodioxol-5-ol[no description available]low00benzodioxoles
1,3-benzodioxol-5-yl-[2-(phenylmethylthio)-4,5-dihydroimidazol-1-yl]methanone[no description available]low00benzodioxoles
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide[no description available]low00benzamides;
benzodioxoles;
imidazoles;
pyridines		EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
psi-baptigenin[no description available]low007-hydroxyisoflavones;
benzodioxoles		antiprotozoal drug;
plant metabolite
savinin[no description available]low00benzodioxoles;
gamma-lactone;
lignan		anti-inflammatory agent;
anticoronaviral agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
plant metabolite;
T-cell proliferation inhibitor
N-(1,3-benzodioxol-5-yl)-2-(5-methyl-2-furanyl)-3-imidazo[1,2-a]pyrazinamine[no description available]low00benzodioxoles
Piperanine[no description available]low00benzodioxoles
piperlonguminine[no description available]low00benzodioxoles
piperic acid[no description available]low00alpha,beta-unsaturated monocarboxylic acid;
benzodioxoles		plant metabolite
pipercallosidine[no description available]low00alkaloid;
benzodioxoles;
enamide;
secondary carboxamide		apoptosis inducer;
metabolite;
plant metabolite
Pipercide[no description available]low00benzodioxoles
dehydropipernonaline[no description available]low00benzodioxoles
guineensine[no description available]low00benzodioxoles
1-(1,3-benzodioxol-5-yl)-3-(6-methyl-2-pyridinyl)urea[no description available]low00benzodioxoles
N-(1,3-benzodioxol-5-yl)-2-methyl-3-pyrazolecarboxamide[no description available]low00benzodioxoles
N-(1,3-benzodioxol-5-yl)-3-[(2-methoxy-1-oxoethyl)amino]-2-benzofurancarboxamide[no description available]low00benzodioxoles
pipernonaline[no description available]low00benzodioxoles
saracatinib[no description available]low00aromatic ether;
benzodioxoles;
diether;
N-methylpiperazine;
organochlorine compound;
oxanes;
quinazolines;
secondary amino compound		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
radiosensitizing agent
manassantin b[no description available]low00benzodioxoles;
dimethoxybenzene;
lignan;
oxolanes;
secondary alcohol		antineoplastic agent;
metabolite
retrofractamide a[no description available]low00benzodioxoles
4,5-dihydropiperlonguminine[no description available]low00benzodioxoles
[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-[(2S,3S,4R)-4-(1-benzothiophen-3-yl)-2-ethoxy-3-(3-hydroxypropyl)-3,4-dihydro-2H-pyran-6-yl]methanone[no description available]low00benzodioxoles
[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-[(2R,4R)-4-(1-benzothiophen-3-yl)-2-[[4-(hydroxymethyl)phenyl]methoxy]-3,4-dihydro-2H-pyran-6-yl]methanone[no description available]low00benzodioxoles
[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-[(2S,4S)-4-(1-benzothiophen-3-yl)-2-[[4-(hydroxymethyl)phenyl]methoxy]-3,4-dihydro-2H-pyran-6-yl]methanone[no description available]low00benzodioxoles
[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-[(2R,4R)-4-(4-bromophenyl)-2-(4-hydroxybutoxy)-3,4-dihydro-2H-pyran-6-yl]methanone[no description available]low00benzodioxoles
[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-[(2R,3R,4S)-4-(1-benzothiophen-3-yl)-2-ethoxy-3-(3-hydroxypropyl)-3,4-dihydro-2H-pyran-6-yl]methanone[no description available]low00benzodioxoles
N-[5-[[2-(2-furanylmethylamino)-2-oxoethyl]thio]-1,3,4-thiadiazol-2-yl]-1,3-benzodioxole-5-carboxamide[no description available]low00benzodioxoles
lumacaftor[no description available]low00aromatic amide;
benzodioxoles;
benzoic acids;
cyclopropanes;
organofluorine compound;
pyridines		CFTR potentiator;
orphan drug
jzl 184[no description available]low00benzodioxoles
Retrofractamide C[no description available]low00benzodioxoles
1-[(2R,3S)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-3-(3,5-dimethyl-4-isoxazolyl)urea[no description available]low00benzodioxoles
3-(1,3-benzodioxol-5-yl)-1-[[(2S,3S)-10-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methylurea[no description available]low00benzodioxoles
methylone[no description available]low00benzodioxoles
as 604850[no description available]low00benzodioxoles
biliatresone[no description available]low00aromatic ether;
aromatic ketone;
benzodioxoles;
enone;
phenols		plant metabolite;
toxin
AZ3451[no description available]low00benzimidazoles;
benzodioxoles;
nitrile;
organobromine compound;
secondary carboxamide		anti-inflammatory agent;
autophagy inducer;
PAR2 negative allosteric modulator
((5z)5-(1,3-benzodioxol-5-yl)methylene-2-phenylamino-3,5-dihydro-4h-imidazol-4-one)[no description available]low00benzodioxoles;
imidazolone;
substituted aniline		autophagy inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
EC 2.7.12.1 (dual-specificity kinase) inhibitor;
neuroprotective agent;
nootropic agent
5-(1,3-benzodioxol-5-yl)-3-phenyl-2-sulfanylidene-4H-thiazolo[4,5-d]pyrimidin-7-one[no description available]low00benzodioxoles
ConditionIndicatedRelationship StrengthStudiesTrials
Abnormalities, Autosome0low20
Abnormalities, Chromosomal0low20
Abnormalities, Chromosome0low20
Acute Confusional Senile Dementia0low10
Acute Disease0low40
Acute Edematous Pancreatitis0low10
Acute Liver Injury, Drug-Induced0low50
Acute Lung Injury0low10
Acute Pancreatitis0low10
Adenocarcinoma0low10
Adenocarcinoma of Lung0low10
Adenocarcinoma, Basal Cell0low10
Adenocarcinoma, Granular Cell0low10
Adenocarcinoma, Oxyphilic0low10
Adenocarcinoma, Tubular0low10
Adenoma, Malignant0low10
Adjuvant Arthritis0low20
Age-Related Memory Disorders0low20
Aging0low10
Akinetic-Rigid Variant of Huntington Disease0low10
Alloxan Diabetes0low50
Alveolitis, Fibrosing0low20
Alzheimer Dementia0low10
Alzheimer Disease0low10
Alzheimer Disease, Early Onset0low10
Alzheimer Disease, Late Onset0low10
Alzheimer Sclerosis0low10
Alzheimer Syndrome0low10
Alzheimer Type Senile Dementia0low10
Alzheimer-Type Dementia (ATD)0low10
Alzheimer's Disease0low10
Alzheimer's Disease, Focal Onset0low10
Alzheimer's Diseases0low10
Anoxemia0low10
Anoxia0low10
Anxiety0low10
Anxiety Disorders0low10
Anxiety Neuroses0low10
Anxiety States, Neurotic0low10
Aortic Diseases0low10
Apnea, Obstructive Sleep0low10
Apoplexy0low10
Arthritis, Adjuvant0low20
Arthritis, Adjuvant-Induced0low20
Arthritis, Collagen-Induced0low20
Arthritis, Degenerative0low10
Arthritis, Experimental0low20
Arthritis, Rheumatoid0low10
Arthroses0low10
Arthrosis0low10
Asymmetric Diabetic Proximal Motor Neuropathy0low10
Atherogenesis0low40
Atherosclerosis0low40
Atherosclerotic Parkinsonism0low10
Autosome Abnormalities0low20
Benign Neoplasms0low20
Benign Neoplasms, Brain0low10
Bile Duct Obstruction0low10
Biliary Stasis0low10
Blood Clot0low10
Blood Poisoning0low10
Blood Pressure, High0low20
Bloodstream Infection0low10
Body Weight0low110
Bowel Diseases, Inflammatory0low20
Brain Cancer0low10
Brain Ischemia0low10
Brain Metastases0low10
Brain Neoplasm, Primary0low10
Brain Neoplasms0low10
Brain Neoplasms, Benign0low10
Brain Neoplasms, Malignant0low10
Brain Neoplasms, Malignant, Primary0low10
Brain Neoplasms, Primary Malignant0low10
Brain Tumor, Primary0low10
Brain Tumor, Recurrent0low10
Brain Tumors0low10
Breast Cancer0low20
Breast Carcinoma0low20
Breast Neoplasms0low20
Breast Tumors0low20
Cancer0low20
Cancer of Brain0low10
Cancer of Breast0low20
Cancer of Cervix0low10
Cancer of Colon0low20
Cancer of Kidney0low10
Cancer of Liver0low10
Cancer of Lung0low10
Cancer of Skin0low30
Cancer of Stomach0low50
Cancer of the Brain0low10
Cancer of the Breast0low20
Cancer of the Cervix0low10
Cancer of the Colon0low20
Cancer of the Kidney0low10
Cancer of the Liver0low10
Cancer of the Lung0low10
Cancer of the Skin0low30
Cancer of the Stomach0low50
Cancer of the Uterine Cervix0low10
Cancer, Hepatocellular0low10
Carbon Tetrachloride Poisoning0low10
Carcinoma0low10
Carcinoma, Anaplastic0low10
Carcinoma, Cribriform0low10
Carcinoma, Ehrlich Tumor0low10
Carcinoma, Epidermoid0low30
Carcinoma, Granular Cell0low10
Carcinoma, Hepatocellular0low10
Carcinoma, Planocellular0low30
Carcinoma, Spindle-Cell0low10
Carcinoma, Squamous0low30
Carcinoma, Squamous Cell0low30
Carcinoma, Tubular0low10
Carcinoma, Undifferentiated0low10
Carcinomatosis0low10
Cardiomyopathies0low10
Cardiomyopathies, Primary0low10
Cardiomyopathies, Secondary0low10
Cardiovascular Diseases0low20
Cardiovascular Stroke0low40
CCl4 Poisoning0low10
Cerebral Ischemia0low10
Cerebral Stroke0low10
Cerebrovascular Accident0low10
Cerebrovascular Accident, Acute0low10
Cerebrovascular Apoplexy0low10
Cerebrovascular Stroke0low10
Cervical Cancer0low10
Cervical Neoplasms0low10
Cervix Cancer0low10
Cervix Neoplasms0low10
Cheilitis0low10
Chemical and Drug Induced Liver Injury0low50
Chemically-Induced Liver Toxicity0low50
Cholestasis0low10
Chorea, Chronic Progressive Hereditary (Huntington)0low10
Chromosomal Aberrations0low20
Chromosome Aberrations0low20
Chromosome Abnormalities0low20
Chromosome-Defective Micronuclei0low10
Chronic Disease0low20
Chronic Illness0low20
Chronic Kidney Diseases0low10
Chronic Kidney Insufficiency0low10
Chronic Progressive Hereditary Chorea (Huntington)0low10
Chronic Renal Diseases0low10
Chronic Renal Insufficiency0low10
Chronically Ill0low20
Cirrhosis0low10
Cirrhosis, Liver0low10
Cocarcinogenesis0low10
Cognition Disorders0low40
Cognitive Decline0low80
Cognitive Dysfunction0low80
Cognitive Impairments0low80
Colitis0low20
Collagen Arthritis0low20
Colon Cancer0low20
Colon Neoplasms0low20
Colonic Cancer0low20
Colonic Neoplasms0low20
Condition, Preneoplastic0low10
Conditions, Preneoplastic0low10
Contact Dermatitis0low10
Corneal Angiogenesis0low10
Corneal Neovascularization0low10
CVA (Cerebrovascular Accident)0low10
Cytogenetic Aberrations0low20
Cytogenetic Abnormalities0low20
Deficiency, Oxygen0low10
Degenerative Diseases, Central Nervous System0low20
Degenerative Diseases, Nervous System0low20
Degenerative Diseases, Neurologic0low20
Degenerative Diseases, Spinal Cord0low20
Degenerative Neurologic Diseases0low20
Degenerative Neurologic Disorders0low20
Dementia, Alzheimer Type0low10
Dementia, Presenile0low10
Dementia, Primary Senile Degenerative0low10
Dementia, Senile0low10
Depression0low10
Dermatitis Venenata0low10
Dermatitis, Contact0low10
Diabetes Mellitus, Experimental0low50
Diabetic Amyotrophy0low10
Diabetic Asymmetric Polyneuropathy0low10
Diabetic Autonomic Neuropathy0low10
Diabetic Feet0low10
Diabetic Foot0low10
Diabetic Glomerulosclerosis0low10
Diabetic Kidney Disease0low10
Diabetic Mononeuropathy0low10
Diabetic Mononeuropathy Simplex0low10
Diabetic Nephropathies0low10
Diabetic Nephropathy0low10
Diabetic Neuralgia0low10
Diabetic Neuropathies0low10
Diabetic Neuropathy, Painful0low10
Diabetic Polyneuropathy0low10
Disease Models, Animal0low200
Diseases, Metabolic0low10
Drug-Induced Acute Liver Injury0low50
Drug-Induced Liver Disease0low50
Drug-Induced Liver Injury0low50
Dyslipidemia0low10
Dyslipidemias0low10
Dyslipoproteinemias0low10
Early Onset Alzheimer Disease0low10
Eczema, Contact0low10
Edema, Pulmonary0low10
Edemas, Pulmonary0low10
Ehrlich Ascites Tumor0low10
Electrolytes0low10
Encephalopathy, Ischemic0low10
Endotoxemia0low10
Epithelial Neoplasms, Malignant0low10
Epithelial Tumors, Malignant0low10
Epithelioma0low10
ER-Negative PR-Negative HER2-Negative Breast Cancer0low20
ER-Negative PR-Negative HER2-Negative Breast Neoplasms0low20
Experimental Diabetes Mellitus0low50
Experimental Hepatoma0low10
Experimental Hepatomas0low10
Experimental Liver Neoplasms0low10
Experimental Lung Inflammation0low10
Experimental Neoplasms0low30
Experimental Radiation Injuries0low20
Extravascular Hemolysis0low20
Familial Alzheimer Disease (FAD)0low10
Fatty Liver0low20
Fatty Liver, Nonalcoholic0low40
Fibroses, Pulmonary0low20
Fibrosis0low10
Fibrosis, Liver0low10
Fibrosis, Pulmonary0low20
Focal Onset Alzheimer's Disease0low10
Foot Ulcer, Diabetic0low10
Gastric Cancer0low50
Gastric Cancer, Familial Diffuse0low50
Gastric Neoplasms0low50
Gastric Ulcer0low10
Genotoxicant-Induced Micronuclei0low10
Glial Cell Tumors0low10
Glioma0low10
Glomerulosclerosis, Diabetic0low10
Haemolysis0low20
Heart Attack0low40
Heavy Metal Poisoning0low10
Hemolysis0low20
Hepatic Cancer0low10
Hepatic Cirrhosis0low10
Hepatic Neoplasms0low10
Hepatic Veno Occlusive Disease0low10
Hepatic Veno-Occlusive Disease0low10
Hepatitis0low10
Hepatitis, Drug-Induced0low50
Hepatitis, Toxic0low50
Hepatocellular Cancer0low10
Hepatocellular Carcinoma0low10
Hepatoma0low10
Hepatoma, Experimental0low10
Hepatoma, Morris0low10
Hepatoma, Novikoff0low10
Hepatomas, Experimental0low10
Human Mammary Carcinoma0low20
Huntington Chorea0low10
Huntington Chronic Progressive Hereditary Chorea0low10
Huntington Disease0low10
Huntington Disease, Akinetic-Rigid Variant0low10
Huntington Disease, Juvenile0low10
Huntington Disease, Juvenile-Onset0low10
Huntington Disease, Late Onset0low10
Huntington's Chorea0low10
Huntington's Disease0low10
Hyperglycemia0low10
Hyperglycemia, Postprandial0low10
Hyperlipemia0low40
Hyperlipidemia0low40
Hyperlipidemias0low40
Hyperplasia0low40
Hypersensitivity, Contact0low10
Hypertension0low20
Hypoxemia0low10
Hypoxia0low10
Idiopathic Diffuse Interstitial Pulmonary Fibrosis0low20
Inflammation0low80
Inflammatory Bowel Diseases0low20
Injuries, Experimental Radiation0low20
Injury, Ischemia-Reperfusion0low10
Injury, Reperfusion0low10
Innate Inflammatory Response0low80
Insulin Resistance0low30
Insulin Sensitivity0low30
Interstitial Cell Tumor0low10
Intracapillary Glomerulosclerosis0low10
Intracranial Neoplasms0low10
Intravascular Hemolysis0low20
Iron Overload0low10
Ischemia-Reperfusion Injury0low10
Ischemia, Cerebral0low10
Ischemic Encephalopathy0low10
Juvenile Huntington Disease0low10
Juvenile-Onset Huntington Disease0low10
Kidney Cancer0low10
Kidney Diseases0low20
Kidney Insufficiency, Chronic0low10
Kidney Neoplasms0low10
Kimmelstiel-Wilson Disease0low10
Kimmelstiel-Wilson Syndrome0low10
Late Onset Alzheimer Disease0low10
Late-Onset Huntington Disease0low10
Leydig Cell Tumor0low10
Lipemia0low40
Lipidemia0low40
Liver Cancer0low10
Liver Cancer, Adult0low10
Liver Cell Carcinoma0low10
Liver Cell Carcinoma, Adult0low10
Liver Cirrhosis0low10
Liver Diseases0low10
Liver Dysfunction0low10
Liver Fibrosis0low10
Liver Injury, Drug-Induced0low50
Liver Injury, Drug-Induced, Acute0low50
Liver Neoplasms0low10
Liver Neoplasms, Experimental0low10
Liver Steatosis0low20
Lobar Pneumonia0low10
Lung Adenocarcinoma0low10
Lung Cancer0low10
Lung Inflammation0low10
Lung Injury, Acute0low10
Lung Neoplasms0low10
Malaria, Falciparum0low10
Malignancy0low20
Malignant Epithelial Neoplasms0low10
Malignant Glioma0low10
Malignant Melanoma0low40
Malignant Neoplasm of Breast0low20
Malignant Neoplasms0low20
Malignant Neoplasms, Brain0low10
Malignant Primary Brain Neoplasms0low10
Malignant Primary Brain Tumors0low10
Malignant Tumor of Breast0low20
Mammary Cancer0low20
Mammary Carcinoma, Human0low20
Mammary Neoplasm, Human0low20
Mammary Neoplasms, Human0low20
Melanoma0low40
Memory Deficits0low20
Memory Disorder, Semantic0low20
Memory Disorder, Spatial0low20
Memory Disorders0low20
Memory Disorders, Age-Related0low20
Memory Loss0low20
Menopause0low10
Menopause, Premature0low10
Mental Deterioration0low80
Metabolic Diseases0low10
Micronuclei, Chromosome-Defective0low10
Micronuclei, Genotoxicant-Induced0low10
Micronucleus, Chromosome-Defective0low10
Mild Cognitive Impairment0low80
Mild Neurocognitive Disorder0low80
Mixed Glioma0low10
MODS0low10
Mononeuropathy, Diabetic0low10
Multiple Organ Dysfunction Syndrome0low10
Multiple Organ Failure0low10
Myocardial Diseases0low10
Myocardial Diseases, Primary0low10
Myocardial Diseases, Secondary0low10
Myocardial Infarct0low40
Myocardial Infarction0low40
Myocardiopathies0low10
NAFLD0low40
Neoplasia0low20
Neoplasm0low20
Neoplasms0low20
Neoplasms, Benign0low20
Neoplasms, Brain0low10
Neoplasms, Brain, Benign0low10
Neoplasms, Brain, Malignant0low10
Neoplasms, Brain, Primary0low10
Neoplasms, Breast0low20
Neoplasms, Cervical0low10
Neoplasms, Cervix0low10
Neoplasms, Colonic0low20
Neoplasms, Experimental0low30
Neoplasms, Experimental Liver0low10
Neoplasms, Gastric0low50
Neoplasms, Hepatic0low10
Neoplasms, Intracranial0low10
Neoplasms, Kidney0low10
Neoplasms, Liver0low10
Neoplasms, Lung0low10
Neoplasms, Malignant Epithelial0low10
Neoplasms, Pulmonary0low10
Neoplasms, Skin0low30
Neoplasms, Stomach0low50
Nervous System Degenerative Diseases0low20
Neuralgia, Diabetic0low10
Neuroblastoma0low20
Neurodegenerative Diseases0low20
Neurodegenerative Disorders0low20
Neurologic Degenerative Conditions0low20
Neurologic Degenerative Diseases0low20
Neurologic Diseases, Degenerative0low20
Neuroses, Anxiety0low10
Nodular Glomerulosclerosis0low10
Non-alcoholic Fatty Liver Disease0low40
Nonalcoholic Fatty Liver Disease0low40
Nonalcoholic Steatohepatitis0low40
Obesity0low70
Obstructive Sleep Apnea0low10
Obstructive Sleep Apnea Syndrome0low10
Organ Dysfunction Syndrome, Multiple0low10
Organ Failure, Multiple0low10
OSAHS0low10
Osteoarthritis0low10
Osteoarthrosis0low10
Osteoarthrosis Deformans0low10
Overinclusion0low40
Oxygen Deficiency0low10
Palsy0low10
Pancreatic Parenchyma with Edema0low10
Pancreatic Parenchymal Edema0low10
Pancreatitis0low10
Pancreatitis, Acute0low10
Pancreatitis, Acute Edematous0low10
Papilloma0low20
Papilloma, Squamous Cell0low20
Papillomatosis0low20
Paralysis0low10
Parkinson Disease, Secondary0low10
Parkinson Disease, Secondary Vascular0low10
Parkinson Disease, Symptomatic0low10
Parkinsonism, Secondary0low10
Parkinsonism, Symptomatic0low10
Peripancreatic Fat Necrosis0low10
Plasmodium falciparum Malaria0low10
Plegia0low10
Pneumonia0low10
Pneumonia, Lobar0low10
Pneumonitis0low10
Poisoning0low10
Poisoning, Blood0low10
Poisoning, Carbon Tetrachloride0low10
Poisoning, CCl40low10
Postprandial Hyperglycemia0low10
Precancerous Conditions0low10
Preneoplastic Condition0low10
Preneoplastic Conditions0low10
Presenile Alzheimer Dementia0low10
Primary Brain Neoplasms0low10
Primary Malignant Brain Neoplasms0low10
Primary Malignant Brain Tumors0low10
Primary Myocardial Diseases0low10
Primary Senile Degenerative Dementia0low10
Progressive Chorea, Chronic Hereditary (Huntington)0low10
Progressive Chorea, Hereditary, Chronic (Huntington)0low10
Pulmonary Cancer0low10
Pulmonary Edema0low10
Pulmonary Edemas0low10
Pulmonary Fibroses0low20
Pulmonary Fibrosis0low20
Pulmonary Inflammation0low10
Pulmonary Neoplasms0low10
Pyaemia0low10
Pyemia0low10
Pyohemia0low10
Radiation Injuries, Experimental0low20
Renal Cancer0low10
Renal Insufficiency, Chronic0low10
Renal Neoplasms0low10
Reperfusion Damage0low10
Reperfusion Injury0low10
Retention Disorders, Cognitive0low20
Rheumatoid Arthritis0low10
Sarcoma0low10
Sarcoma, Epithelioid0low10
Sarcoma, Soft Tissue0low10
Sarcoma, Spindle Cell0low10
Secondary Myocardial Diseases0low10
Secondary Parkinsonism0low10
Secondary Vascular Parkinson Disease0low10
Semantic Memory Disorder0low20
Senile Dementia, Acute Confusional0low10
Senile Dementia, Alzheimer Type0low10
Sensitivity and Specificity0low10
Sensitivity, Contact0low10
Sepsis0low10
Septicemia0low10
Severe Sepsis0low10
Sinusoidal Obstruction Syndrome0low10
Skin Aging0low10
Skin Cancer0low30
Skin Neoplasms0low30
Sleep Apnea Hypopnea Syndrome0low10
Sleep Apnea Syndrome, Obstructive0low10
Sleep Apnea, Obstructive0low10
Spatial Memory Disorder0low20
Spermatic Cord Torsion0low10
Squamous Cell Carcinoma0low30
Steatohepatitis0low20
Steatosis of Liver0low20
Stomach Cancer0low50
Stomach Neoplasms0low50
Stomach Ulcer0low10
Streptozocin Diabetes0low50
Streptozotocin Diabetes0low50
Stroke0low10
Stroke, Acute0low10
Symmetric Diabetic Proximal Motor Neuropathy0low10
Symptom Cluster0low10
Symptomatic Parkinson Disease0low10
Syndrome0low10
Syndrome, Obstructive Sleep Apnea0low10
Syndrome, Sleep Apnea, Obstructive0low10
Syndrome, Upper Airway Resistance, Sleep Apnea0low10
Testicular Torsion0low10
Thesaurismosis0low10
Thrombosis0low10
Thrombus0low10
Todd Paralysis0low10
Todd's Paralysis0low10
Torsion Of Testicular Cord0low10
Toxic Hepatitis0low50
Triple Negative Breast Cancer0low20
Triple Negative Breast Neoplasms0low20
Triple-Negative Breast Cancer0low20
Triple-Negative Breast Neoplasm0low20
Tumors0low20
Tumors, Breast0low20
Upper Airway Resistance Sleep Apnea Syndrome0low10
Uterine Cervical Cancer0low10
Uterine Cervical Neoplasms0low10
Vascular Accident, Brain0low10
Veno-Occlusive Disease, Hepatic0low10
Visceral Steatosis0low20
Weight Gain0low30
Wet Lung0low10

Research Highlights

Safety/Toxicity (15)

ArticleYear
Sesamol attenuates bleomycin-induced pulmonary toxicity and fibrosis in experimental animals.
Journal of biochemical and molecular toxicology, Volume: 37, Issue: 11		2023
Sesamol protects the function and structure of rat ovaries against side effects of cyclophosphamide by decreasing oxidative stress and apoptosis.
The journal of obstetrics and gynaecology research, Volume: 48, Issue: 7		2022
Neuroprotective effect of sesamol against aluminum nanoparticle-induced toxicity in rats.
Environmental science and pollution research international, Volume: 28, Issue: 38		2021
Role of L-Type Amino Acid Transporter 1 (LAT1) for the Selective Cytotoxicity of Sesamol in Human Melanoma Cells.
Molecules (Basel, Switzerland), Oct-27, Volume: 24, Issue: 21		2019
Sesamin and sesamolin reduce amyloid-β toxicity in a transgenic Caenorhabditis elegans.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, Volume: 107		2018
Sesamol loaded solid lipid nanoparticles: a promising intervention for control of carbon tetrachloride induced hepatotoxicity.
BMC complementary and alternative medicine, May-03, Volume: 15		2015
Sesamol attenuates genotoxicity in bone marrow cells of whole-body γ-irradiated mice.
Mutagenesis, Volume: 30, Issue: 5		2015
Hepatoprotective effects of sesamol loaded solid lipid nanoparticles in carbon tetrachloride induced sub-chronic hepatotoxicity in rats.
Environmental toxicology, Volume: 31, Issue: 5		2016
Sesamol ameliorates cyclophosphamide-induced hepatotoxicity by modulating oxidative stress and inflammatory mediators.
Anti-cancer agents in medicinal chemistry, Volume: 14, Issue: 7		2014
Beneficial effect of sesame oil on heavy metal toxicity.
JPEN. Journal of parenteral and enteral nutrition, Volume: 38, Issue: 2		2014
Sesamol prevents doxorubicin-induced oxidative damage and toxicity on H9c2 cardiomyoblasts.
The Journal of pharmacy and pharmacology, Volume: 65, Issue: 7		2013
Efficacy of sesamol on plasma and tissue lipids in isoproterenol-induced cardiotoxicity in Wistar rats.
Archives of pharmacal research, Volume: 35, Issue: 8		2012
Anti-hepatotoxic effects of 3,4-methylenedioxyphenol and N-acetylcysteine in acutely acetaminophen-overdosed mice.
Human & experimental toxicology, Volume: 30, Issue: 10		2011
Apoptosis-inducing action of two products from oxidation of sesamol, an antioxidative constituent of sesame oil: a possible cytotoxicity of oxidized antioxidant.
Toxicology in vitro : an international journal published in association with BIBRA, Volume: 24, Issue: 6		2010
Effect of sesamol on radiation-induced cytotoxicity in Swiss albino mice.
Mutation research, Dec-10, Volume: 611, Issue: 1-2		2006
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pharmacokinetics (1)

ArticleYear
Role of sesamol-loaded floating beads in gastric cancers: a pharmacokinetic and biochemical evidence.
Journal of microencapsulation, Volume: 32, Issue: 5		2015
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (7)

ArticleYear
Encapsulation of sesamol in phosphatidyl choline micelles: Enhanced bioavailability and anti-inflammatory activity.
Food chemistry, Aug-01, Volume: 228		2017
Sesamol Induces Apoptosis by Altering Expression of Bcl-2 and Bax Proteins and Modifies Skin Tumor Development in Balb/c Mice.
Anti-cancer agents in medicinal chemistry, Volume: 17, Issue: 5		2017
Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends.
Journal of medicinal chemistry, Apr-14, Volume: 59, Issue: 7		2016
Sesamol loaded solid lipid nanoparticles: a promising intervention for control of carbon tetrachloride induced hepatotoxicity.
BMC complementary and alternative medicine, May-03, Volume: 15		2015
Hepatoprotective effects of sesamol loaded solid lipid nanoparticles in carbon tetrachloride induced sub-chronic hepatotoxicity in rats.
Environmental toxicology, Volume: 31, Issue: 5		2016
Elimination and metabolism of sesamol, a bioactive compound in sesame oil, in rats.
Molecular nutrition & food research, Volume: 53 Suppl 1		2009
Bioavailability and tissue distribution of sesamol in rat.
Journal of agricultural and food chemistry, Aug-27, Volume: 56, Issue: 16		2008
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (6)

ArticleYear
Antioxidant, lipid lowering, and membrane stabilization effect of sesamol against doxorubicin-induced cardiomyopathy in experimental rats.
BioMed research international, Volume: 2013		2013
Sesamol induces apoptosis in human platelets via reactive oxygen species-mediated mitochondrial damage.
Biochimie, Volume: 95, Issue: 11		2013
Modulatory effect of sesamol on DOCA-salt-induced oxidative stress in uninephrectomized hypertensive rats.
Molecular and cellular biochemistry, Volume: 379, Issue: 1-2		2013
Effects of sesamol on apoptosis and steroidogenesis in MA-10 mouse Leydig tumor cells.
Journal of agricultural and food chemistry, Sep-28, Volume: 59, Issue: 18		2011
Anti-hepatotoxic effects of 3,4-methylenedioxyphenol and N-acetylcysteine in acutely acetaminophen-overdosed mice.
Human & experimental toxicology, Volume: 30, Issue: 10		2011
The protective effect of sesamol against mitochondrial oxidative stress and hepatic injury in acetaminophen-overdosed rats.
Shock (Augusta, Ga.), Volume: 32, Issue: 1		2009
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]